IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
May 13, 2024 09:00 ET
|
Imunon, Inc.
Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 ...
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024 08:00 ET
|
Imunon, Inc.
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on...
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
May 08, 2024 08:00 ET
|
Imunon, Inc.
Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J.,...
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
May 06, 2024 11:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
April 18, 2024 08:30 ET
|
Imunon, Inc.
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc....
IMUNON Reports Compliance with Nasdaq Listing Requirements
April 11, 2024 08:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated...
IMUNON Reports 2023 Financial Results and Provides Business Update
March 28, 2024 08:00 ET
|
Imunon, Inc.
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on...
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
March 25, 2024 08:30 ET
|
Imunon, Inc.
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
March 21, 2024 17:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
IMUNON Files IND Application to Begin Human Testing of IMNN-101
March 13, 2024 08:00 ET
|
Imunon, Inc.
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA ...